Liposomal delivery of antigen to human dendritic cells

Vaccine

Volumn 21, Issue 9-10, 2003, Pages 883-890

  Copland, Melissa J ^a   Baird, Margaret A ^a   Rades, Thomas ^a   McKenzie, Judith L ^b   Becker, Bernd ^c   Reck, Folkert ^c   Tyler, Peter C ^c   Davies, Nigel M ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c CALLAGHAN INNOVATION   (New Zealand)

Author keywords

Dendritic cells; Immunotherapy; Liposomes

Indexed keywords

ANTIGEN; B7 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CELL SURFACE MARKER; FLUORESCEIN ISOTHIOCYANATE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLIPOSOME; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MANNOSE; OVALBUMIN;

CELL ACTIVATION; CELL CULTURE; CELL MATURATION; CONFERENCE PAPER; CONTROLLED STUDY; DENDRITIC CELL; DRUG CONJUGATION; DRUG FORMULATION; DRUG UPTAKE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

ANTIGEN PRESENTATION; ANTIGENS; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; CELL DIFFERENTIATION; CELLS, CULTURED; DENDRITIC CELLS; DRUG DELIVERY SYSTEMS; FLUORESCEIN-5-ISOTHIOCYANATE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOGLOBULINS; LIPOSOMES; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; OVALBUMIN; SOLUTIONS; T-LYMPHOCYTES; TETANUS TOXOID;

EID: 0037435875     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00536-4     Document Type: Conference Paper

References (23)

1. Banchereau J., Briere F., Caux C.et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:2000;767-811.
2. Cella M., Sallusto F., Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol. 9:1997;10-16.
3. Zhou L., Tedder T. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J. Immunol. 158:1995;3821-3835.
4. Hart D.N.J. Dendritic cells: unique leukocyte populations, which control the primary immune response. Blood. 90:1997;3245-3287.
5. Timmerman J.M., Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med. 50:1999;507-529.
6. Nestle F., Alijagic S., Gilliet M.et al. Vaccination of melanoma patients with peptide- or tumour lysate-pulsed dendritic cells. Nat. Med. 4:1998;328-332.
7. Salgaller M., Lodge P. Use of cellular and cytokine adjuvants in the immunotherapy of cancer. J. Surg. Oncol. 68:1998;122-138.
8. Celluzzi C., Mayordomo J., Storkus W., Lotze M., Falo L. Jr. Peptide-pulsed dendritic cells induce antigen-specific, CLT-mediated protective tumour immunity. J. Exp. Med. 13:1996;283-287.
9. Shen Z., Reznikoff G., Dranoff G., Rock K.L. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J. Immunol. 158:1997;2723-2730.
10. Faulkner L., Buchan G., Baird M. Interleukin-10 does not affect phagocytosis of particulate antigen by bone marrow derived dendritic cells but does impair antigen presentation. Immunology. 99:2000;523-531.
11. Stubbs A.C., Martin K.S., Coeshott C.et al. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat. Med. 7:2001;625-629.
12. 5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188:1998;1359-1368.
13. Avrameas A., McIlroy D., Hosmalin A.et al. Expression of a mannose/fucose membrane lectin on human dendritic cells. Eur. J. Immunol. 26:1996;394-400.
14. Kery V., Krepinsky J., Warren C., Capek P., Stahl P. Ligand recognition by purified human mannose receptor. Arch. Biochem. Biophys. 298:1992;49-55.
15. Sallusto F., Cella M., Danieli C., Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate marcomolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 182:1995;389-400.
16. Tan M.C., Mommaas A.M., Mommaas J.W.et al. Mannose receptor-mediated uptake of antigens strongly enhances HLA class II-restricted antigen presentation by cultured dendritic cells. Eur. J. Immunol. 27:1997;2426-2435.
17. Engering A.J., Cella M., Fluitsma D.et al. The mannose receptor functions as a high capacity and broad specificity antigen receptor in human dendritic cells. Eur. J. Immunol. 27:1997;2417-2425.
18. Diebold S., Kursa M., Wagner E., Cotton M., Zenke M. Mannose polyethylenimine conjugates for targeted DNA delivery into dendritic cells. J. Biol. Chem. 274:1999;19087-19094.
19. Becker B., Furneaux R., Reck F., Zubkov O. A simple synthesis of 8-(methoxycarbonyl)octyl 3,6-di-O-(α-D-mannopyranosyl)-α-D-mannopyranoside and derivatives and their use in the preparation of neoglycoconjugates. Carbohydr. Res. 315:1999;148-158.
20. Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumour necrosis factor α J. Exp. Med. 179:1994;1109-1118.
21. Morel A., Quaratino S., Douek D., Londei M. Split activity of interleukin-10 on antigen capture and antigen presentation by human dendritic cells: definition of a maturative step. Eur. J. Immunol. 27:1997;26-34.
22. Stahl P., Ezekowitz R. The mannose receptor is a pattern recognition receptor involved in host defence. Curr. Opin. Immunol. 10:1998;50-55.
23. Machy P., Serre K., Leserman L. Class I-restricted presentation of exogenous antigen acquired by Fcγ receptor-mediated endocytosis is regulated in dendritic cells. Eur. J. Immunol. 30:2000;848-857.